• Mashup Score: 2

    Viz.ai closes the gaps between patients, clinicians, and life-saving treatments with its leading-edge AI-powered care coordination solution.

    Tweet Tweets with this article
    • ICYMI: https://t.co/eWTlguTh8t announced it has received de novo approval from the FDA for its #artificialintelligence module for the early detection #hypertrophiccardiomyopathy #cardiotwitter https://t.co/Jh2FAYGcST

  • Mashup Score: 7

    Viz.ai closes the gaps between patients, clinicians, and life-saving treatments with its leading-edge AI-powered care coordination solution.

    Tweet Tweets with this article
    • RT @CardiologyToday: ICYMI: https://t.co/eWTlguTh8t announced it has received de novo approval from the FDA for its #artificialintelligence…

    • ICYMI: https://t.co/eWTlguTh8t announced it has received de novo approval from the FDA for its #artificialintelligence module for the early detection #hypertrophiccardiomyopathy #cardiotwitter https://t.co/Jh2FAYGcST

  • Mashup Score: 0

    Viz.ai closes the gaps between patients, clinicians, and life-saving treatments with its leading-edge AI-powered care coordination solution.

    Tweet Tweets with this article
    • https://t.co/eWTlguTh8t announced it has received de novo approval from the FDA for its #artificialintelligence module for the early detection #hypertrophiccardiomyopathy #cardiotwitter https://t.co/Jh2FAYGcST

  • Mashup Score: 3

    Electrophysiologists John Mandrola, MD. and Rachel Lampert, MD, review the LIVE-HCM study comparing vigorous and nonvigorous exercise in people with hypertrophic cardiomyopathy.

    Tweet Tweets with this article
    • .@DrJohnM interviews Dr Rachel Lampert of @YaleCardiology about the LIVE HCM trial on vigorous #exercise in patients with #Hypertrophiccardiomyopathy #WCCardio #ACC23 https://t.co/JCrORUF9wB